Novartis Inks Deal With Alnylam and 4 Stocks Riding 52-Week Highs

Vail Resorts, Inc. (NYSE:MTN): The company has released a statement as follows: “Our guidance for fiscal year 2013 anticipates a return to more normal weather conditions and the continuation of a challenging, but stable economic environment. Based on our current estimates, our fiscal year 2013 guidance range anticipates Resort Reported EBITDA of between $260 million and $270 million, reflecting a 27 to 32 percent increase over Resort Reported EBITDA in fiscal year 2012. Our Real Estate segment results are impacted in any given year by the timing and mix of real estate sold and closed. For fiscal year 2013, we are estimating Real Estate Reported EBITDA of negative $9 million to negative $17 million, including approximately $2 million of non-cash stock-based compensation expense. Included in these estimates are Net Real Estate Cash Flow of $15 million to $25 million, defined as Real Estate Reported EBITDA, plus non-cash real estate cost of sales, plus non-cash stock-based compensation expense, plus change in real estate deposits less investment in real estate. Net income attributable to Vail Resorts, Inc. is expected to be in a range of $50 million to $60 million in fiscal year 2013.” Shares closed up 8.23 percent on the day at $57.07, and have traded in a 52-week range of $35.27 to $56.99.

Novartis AG (NYSE:NVS) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported Tuesday that they have entered into a letter agreement under which Alnylam agreed that, if during the next five years Novartis is ineligible to sell shares of the firm’s common stock it holds, not counting ineligibility from the purchase by Novartis or its affiliates of additional shares of its common stock, Novartis will have registration rights for such shares similar to those rights set forth in the Investor Rights Agreement that was dated September 6, 2005. The agreement was executed at the same time as the sale by Novartis of 1.55 million Alnylam shares, which the latter expects will result in the loss of Novartis’ existing demand and piggyback registration rights, along with its subscription rights under the Investor Rights Agreement. Following the divestiture, Novartis said that it holds 4.05 million shares of Alnylam’s common stock. Shares closed up 0.18 percent on the day at $61.45, having been traded in a 52-week range of $51.20 to $61.50.

Royal Caribbean Cruises Ltd. (NYSE:RCL) says that Brian Rice has been promoted to Vice Chairman and Chief Financial Officer of the company. In this expanded function, Rice will continue to oversee the finance unit, but will also assume responsibility for the firm’s supply chain department, and also concentrating more on strategic issues. Shares closed up 0.56 percent on the day at $30.59, and have traded in a 52-week range of $18.70 to $31.96.

Ramtron International Corporation (NASDAQ:RMTR): Cypress Semiconductor Corporation (NASDAQ:CY) reported that, in concurrence with its previously announced merger arrangement with Ramtron, it has raised the offer price in its all-cash tender offer to purchase all of the outstanding shares of Ramtron to $3.10 per share and has also extended the expiration date of the bid to 12:00 midnight, Eastern Daylight Time, on October 9, 2012, unless further extended. This offer has been set to expire at 5:00 p.m., on September 25, 2012. As of 4:00 p.m. on September 24th, 5,731,472 shares of Ramtron had been tendered and not withdrawn pursuant to the offer. Shares closed down 0.32 percent on the day at $3.08, and have traded in a 52-week range of $1.65 to $3.10.

Sprint Nextel Corporation (NYSE:S) Chief Executive Heins announces that carrier testing of the BlackBerry10 will begin in October. Shares closed down 2.98 percent on the day at $5.53, having been traded in a 52-week range of $2.10 to $5.75.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>